Levoleucovorin clinical trials
Includes 6 studies of Levoleucovorin calcium.
How each study uses Levoleucovorin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 7 Mar 2008 · FUSILEV · NDA 020140 (FDA, Drugs@FDA; as levoleucovorin calcium)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
12 studies that test it; most in 2013 (3)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2002 | 2 |
| 2005 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2020 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 6
Southwest Autism Research & Resource Center (2) · Takeda (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Acrotech Biopharma Inc. (2) · Institute of Cancer Research, United Kingdom (1) · Gruppo Oncologico del Nord-Ovest (1) · Hokkaido Gastrointestinal Cancer Study Group (1) · Universiteit Antwerpen (1)
Often tested with
Tested in the same studies.
Fluorouracil (5) · Oxaliplatin (4) · Panitumumab (2) · Pralatrexate (2) · Bevacizumab (1) · Irinotecan (1) · Trifluridine tipiracil drug combination (1) · Tucatinib (1)
Related medicines
As reviewed, each with the page that says it.
- An enantiomer of Leucovorin source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Levoleucovorin is the comparator. A study of two new drugs counts under both.
- 1Trastuzumab rezetecan · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · next primary completion Sep 2029
- 1Anti-HER2 Antibody-drug Conjugate BL-M07D1 · Sichuan Baili Pharmaceutical Co., Ltd. · next primary completion Dec 2028
- 1Izalontamab brengitecan · Sichuan Baili Pharmaceutical Co., Ltd. · next primary completion Dec 2028
Reaching primary completion within a year · 1
Studies that test Levoleucovorin.
- Jan 2027Treatment of Social and Language Deficits With Leucovorin for Young Children With AutismPhase 2 · Southwest Autism Research & Resource Center
Studies
Open first, then newest update. How each study uses Levoleucovorin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Treatment of Social and Language Deficits With Leucovorin for Young Children With AutismActive, not recruitingPhase 2Southwest Autism Research & Resource CenterNCT04060030Written as Levoleucovorin CalciumHow we know
- Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin CalciumActive, not recruitingPhase 2Southwest Autism Research & Resource CenterNCT04060017Written as Levoleucovorin CalciumHow we know
- Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer PatientsSuspendedPhase 2Gruppo Oncologico del Nord-OvestNCT05062889Written as L-LeucovorinHow we know
- Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRCCompletedPhase 3TakedaNCT02394795Written as oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumabHow we know
- Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®WithdrawnPhase 1Acrotech Biopharma Inc.NCT01820091Written as FusilevHow we know
- Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving FolotynWithdrawnPhase 1Acrotech Biopharma Inc.NCT01789723Written as FusilevHow we know
- Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal CarcinomaCompletedPhase 2TakedaNCT02337946Written as oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumabHow we know
- Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal CancerStatus unknownPhase 3Universiteit AntwerpenNCT01895257Written as systemic chemotherapy LV5FU2How we know
- Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically RemovedCompletedPhase 3Institute of Cancer Research, United KingdomNCT00005586Written as L-leucovorinHow we know
- Study Evaluating Isovorin in Advanced/Recurrent Gastric CancerCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00195572Written as IsovorinHow we know
- Study Evaluating Isovorin in Colon CancerCompletedPhase 3Wyeth is now a wholly owned subsidiary of PfizerNCT00195585Written as IsovorinHow we know
- Feasibility Study of mFOLFOX6 in Patients With Advanced Colorectal CancerTerminatedPhase 2Hokkaido Gastrointestinal Cancer Study GroupNCT00209703Written as l-LeucovorinHow we know
Given beside what is tested · 48 — Levoleucovorin is usual care or a partner of the new treatment
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2National Cancer Institute (NCI)NCT06317662Written as LevoleucovorinHow we know
- Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06469944Written as LevoleucovorinHow we know
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06780111Written as LevoleucovorinHow we know
- A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06997497Written as Leucovorin/levofolinate calciumHow we know
- A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received ChemotherapyRecruitingPhase 3Janssen Research & Development, LLCNCT06750094Written as Leucovorin calcium/LevoleucovorinHow we know
- A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal CancerRecruitingPhase 3Janssen Research & Development, LLCNCT06662786Written as Leucovorin calcium/LevoleucovorinHow we know
- An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2National Cancer Center Hospital EastNCT07018570Written as LevofolinateHow we know
- FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)Not yet recruitingPhase 2Sun Yat-sen UniversityNCT07621497Written as Levofolinic Acid For InjectionHow we know
- A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C MutationNot yet recruitingPhase 2Eli Lilly and CompanyNCT07814417Written as Leucovorin/levofolinate calciumHow we know
- AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2RecruitingPhase 2AstraZenecaNCT06219941Written as l-leucovorinHow we know
- A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal AdenocarcinomaNot yet recruitingPhase 3Ono Pharmaceutical Co., Ltd.NCT07818070Written as LevoleucovorinHow we know
- A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07676162Written as SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and BevacizumabHow we know
- Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingPhase 3Fujian Cancer HospitalNCT06793917Written as Levo-LeucovorinHow we know
- Phase I/II Study of the Combination of Irinotecan and POF (POFI) and TislelizumabRecruitingPhase 1/2Fujian Cancer HospitalNCT05319639Written as Levo-LeucovorinHow we know
- Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal CancerRecruitingPhase 3National Cancer Institute, NaplesNCT06509126Written as L-folinic acidHow we know
- Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric CancerNot yet recruitingPhase 2Fujian Cancer HospitalNCT06197438Written as Levo-LeucovorinHow we know
- A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal CancerActive, not recruitingPhase 3Seagen, a wholly owned subsidiary of PfizerNCT05253651Written as levoleucovorinHow we know
- An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric CancerActive, not recruitingPhase 2National Cancer Center Hospital EastNCT04745988Written as LevofolinateHow we know
- Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedPhase 3Merck Sharp & Dohme LLCNCT04210115Written as levoleucovorinHow we know
- Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal CancerActive, not recruitingPhase 1Ono Pharmaceutical Co., Ltd.NCT06547385Written as Calcium Levofolinate HydratebHow we know
Showing 20 of 48.
As the comparator · 8 — what is tested is compared with Levoleucovorin
- A Clinical Study of SHR-A1811 in Combination With Chemotherapy and Bevacizumab Versus Standard Therapy as First-Line Treatment for Advanced Colorectal CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07676162Written as SHR-A1811, Oxaliplatin, Levo-leucovorin, Fluorouracil and BevacizumabHow we know
- A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailureRecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07606599Written as Calcium levofolinateHow we know
- A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)RecruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT07582315Written as Calcium levofolinateHow we know
- Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)CompletedPhase 3Merck Sharp & Dohme LLCNCT04456699Written as Leucovorin/ levoleucovorinHow we know
- Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic CancerCompletedPhase 2Institut de Recherches Internationales ServierNCT02697058Written as 5-FU/calcium levofolinateHow we know
- PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon CancerCompletedPhase 1/2Isofol Medical ABNCT01681472Written as Levoleucovorin 200 mg/m2How we know
- A Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)CompletedPhase 3Haruhiko FukudaNCT00190515Written as 5FU+l-leucovorinHow we know
- IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal CancerSuspendedPhase 3Hokkaido Gastrointestinal Cancer Study GroupNCT00316745Written as IsovorinHow we know
Codes
What other systems call Levoleucovorin · ClinicalTrials.gg INT008929
- MeSH (NLM) D058766LevoleucovorinConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 990S25980YLEVOLEUCOVORINConfirmed FDA, NLM
- RxNorm 877015One source FDA
- NCI Thesaurus C1559LevoleucovorinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D058766 | Levoleucovorin | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 990S25980Y | LEVOLEUCOVORIN | Confirmed FDA, NLM |
| RxNorm | 877015 | — | One source FDA |
| NCI Thesaurus | C1559 | Levoleucovorin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.